SCHEMBL17033979

SCHEMBL17033979

CCNC(=O)c1cccc(CI)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.51
SMN1; SMN2 Q16637 4/20 0.50
MRGPRX4 Q96LA9 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
KMT2A Q03164 2/20 0.47
GAA P10253 1/20 0.47
HSD17B10 Q99714 1/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
MMP13 P45452 1/20 0.47
MEN1 O00255 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
ROCK2 O75116 2/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
ROCK1 Q13464 1/20 0.46
BRD4 O60885 1/20 0.46
CDK8 P49336 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17033996 0.87 L3MBTL1 (0.65) SMN1; SMN2L3MBTL1KMT2AGAAHSD17B10
SCHEMBL9691071 0.86 KAT6A (0.55) PARP1SMN1; SMN2MRGPRX4L3MBTL1KMT2A
SCHEMBL14233914 0.85 KAT6A (0.58) PARP1SMN1; SMN2MRGPRX4L3MBTL1KMT2A
SCHEMBL9713054 0.84 SMN1; SMN2 (0.67) PARP1SMN1; SMN2L3MBTL1KMT2AGAA
SCHEMBL14081049 0.83 LOXL2 (0.61) PARP1SMN1; SMN2MRGPRX4L3MBTL1KMT2A
SCHEMBL21872371 0.83 L3MBTL1 (0.51) PARP1SMN1; SMN2MRGPRX4L3MBTL1KMT2A
SCHEMBL27272636 0.83 SMN1; SMN2 (0.54) PARP1SMN1; SMN2MRGPRX4L3MBTL1KMT2A
SCHEMBL2542308 0.83 PARP1 (0.51) PARP1SMN1; SMN2MRGPRX4L3MBTL1KMT2A
SCHEMBL13761327 0.83 PARP1 (0.51) PARP1SMN1; SMN2MRGPRX4L3MBTL1KMT2A
SCHEMBL18265510 0.83 SLC7A5 (0.59) MRGPRX4KMT2AMEN1HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2534152-B1 MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-05-02 EP disclosed
US-9557336-B2 Methods and compositions for site-specific labeling of peptides and proteins UNIVERSITY OF ROCHESTER (US) 2017-01-31 US disclosed
US-20150241440-A1 METHODS AND COMPOSITIONS FOR SITE-SPECIFIC LABELING OF PEPTIDES AND PROTEINS NATIONAL SCIENCE FOUNDATION 2015-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150241440-A1 METHODS AND COMPOSITIONS FOR SITE-SPECIFIC LABELING OF PEPTIDES AND PROTEINS PTMS, ACP1, QPCTL PARP1 4650/4885SMN1; SMN2 4029/4885MRGPRX4 4024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.